NCT04932577 (CHiFT) is a Phase 2, PHASE3 clinical trial of Faecal microbiota transplantation in Liver Cirrhosis, sponsored by University of Aarhus.

Who is sponsoring NCT04932577?

NCT04932577 is sponsored by University of Aarhus.

What drugs are being tested in NCT04932577?

Interventions in NCT04932577: Faecal microbiota transplantation, Placebo.

What condition does NCT04932577 study?

NCT04932577 studies Liver Cirrhosis.

Is NCT04932577 still recruiting?

NCT04932577 is currently recruiting now. Last updated 24 January 2025.

Last reviewed 2025-01-24 · How we verify

NCT04932577: CHiFT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Faecal Microbiota Transplantation for Liver Cirrhosis

Recruiting now Phase 2, PHASE3 Last updated 24 January 2025

What this trial tests

Phase 2, PHASE3 trial testing Faecal microbiota transplantation in Liver Cirrhosis in 220 participants. Currently enrolling.

Timeline

1 July 2021

Primary endpoint
31 May 2026

31 May 2027

Quick facts

Lead sponsor	University of Aarhus
Phase	Phase 2, PHASE3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	220
Start date	1 July 2021
Primary completion	31 May 2026
Estimated completion	31 May 2027
Sites	1 location across Denmark

Drugs / interventions tested

Faecal microbiota transplantation
Placebo

Conditions studied

Liver Cirrhosis — all drugs for Liver Cirrhosis →

Sponsor

University of Aarhus

Who can join

Adults 18 to 75, any sex, with Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis. Further, the investigators want to examine the impact of FMT on the gut microbiota, gut barrier function, systemic inflammation, and immune function.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Treatment of liver fibrosis: Past, current, and future.
Zhang CY, Liu S, Yang M. · · 2023 · cited 49× · PMID 37397931 · DOI 10.4254/wjh.v15.i6.755
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.
Hou S, Yu J, Li Y, Zhao D, et al · · 2025 · cited 34× · PMID 40013938 · DOI 10.1002/advs.202413197
Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.
Marroncini G, Naldi L, Martinelli S, Amedei A. · · 2024 · cited 24× · PMID 39061972 · DOI 10.3390/biomedicines12071398
The shaping of gut immunity in cirrhosis.
Muñoz L, Caparrós E, Albillos A, Francés R. · · 2023 · cited 16× · PMID 37122743 · DOI 10.3389/fimmu.2023.1139554
Exploring the Relationship between Liver Disease, Bacterial Translocation, and Dysbiosis: Unveiling the Gut-Liver Axis.
Juanola O, Francés R, Caparrós E. · · 2024 · cited 12× · PMID 38312368 · DOI 10.1159/000535962
Immunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease.
Shen H, Liangpunsakul S, Iwakiri Y, Szabo G, et al · · 2025 · cited 10× · PMID 40399593 · DOI 10.1038/s41423-025-01291-w
Gut microbiota and metabolite interface-mediated hepatic inflammation.
Yang M, Massad K, Kimchi ET, Staveley-O'Carroll KF, et al · · 2024 · cited 10× · PMID 38283696 · DOI 10.1097/in9.0000000000000037
Gut Bacteria in Alcohol-Associated Liver Disease.
Yang Y, Schnabl B. · · 2024 · cited 7× · PMID 39362714 · DOI 10.1016/j.cld.2024.06.008

Verify or expand the search:

Other trials of Faecal microbiota transplantation

Trials testing the same drug.

NCT04924270 — Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases · Phase 2 · recruiting
NCT05742074 — The Effect of Faecal Microbiota Transplantation (FMT) on Eradication of Multidrug Resistant Organisms (MRO) in Intestina · NA · completed
NCT04820413 — Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis · NA · completed
NCT04100291 — Faecal Microbiota Transplantation in the Treatment of Chronic Pouchitis · NA · terminated
NCT02862249 — Trial of Faecal Microbiota Transplantation in Cirrhosis · Phase 3 · completed

Other recruiting trials for Liver Cirrhosis

Currently open trials in the same condition.

NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
NCT07325526 — A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- · Phase 2 · recruiting
NCT07418008 — The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) · recruiting
NCT07201649 — Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcificati · NA · recruiting
NCT07252102 — Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients · NA · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04932577 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 24 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04932577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing